Newbieee,
1) This company has historically indicated what to expect in the coming months. The reason they are silent on this issue is that nothing in the short-term will happen. It is as simple as that.
Full enrollment, end of 2015, 2016, it makes no short-term difference. This company is always behind on their forecasts so if it did not happen until 2017, no one would be shocked. Any way, we are years before results and that is what is needed to move the stock.
2) Company comments about partnerships are worthless. They have been saying the same thing for ten years. They said they wanted one before starting Phase III. How did that work out?
3) Cotara, took a quick look at the old records, I agree $60 mil.
appears to be a reasonable estimate of the cost of the program.
4) Bavi's record is spotty at best. Does not give me or the market much comfort re. whether it will succeed in Phase III.
5) BTD, I am not concerned about approval but massive appreciation of the stock price in the short-term. BTD would do that, FTD clearly does not.
My major point is you have two chances with small bio-tech stocks.
License the technology during the clinical trial process. We cash out and make big money. Most drugs subsequently fail but we do not care since we made our money and are out. That almost happened here but the botched trial took care of that. This company has zero credibility in the market and the only way we can make money is upon approval which at a minimum is three years away.
Even the partnerships they are talking about would just allow us to move other trials faster. It would not be a buyout and I wonder if it would cause the stock price to appreciate that much.
News 
Market Data 
Discover 
